MedTrace Logo

Metformin in Heart Failure Without Diabetes

NCT03331861 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-07-18

Study results available
· View outcomes & findings →

Summary

A pilot clinical research study that will assess the use of the medication metformin for heart failure in patients who are not diabetic and have no evidence of insulin resistance.

Conditions

Interventions

DRUG

Metformin hydrochloride

Metformin starting at 500mg twice a day and increasing to 1000mg twice a day for a total of 6 months

DRUG

Placebo

Similar dosing regime as active comparator

Sponsors & Collaborators

Principal Investigators

  • Barry Fine, MD · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-15
Primary Completion
2021-08-20
Completion
2021-08-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03331861 on ClinicalTrials.gov